Abstract
Accurate prediction of human drug safety remains a major challenge for drug development. Species-difference in drug toxicity represents a main reason for the difficulty in the prediction of human drug toxicity with nonhuman animal models. A combined in vitro-in vivo strategy (IVIVS), using human-based in vitro experimental systems to derive humanspecific information, and animal systems for in vivo variables, may lead to a more accurate prediction of human in vivo drug toxicity. The success of IVIVS requires in vitro models with human-specific drug metabolism, appropriate target cell populations, and relevant endpoints. A novel theory, the Target Cell Initiation Theory for drug-induced organ failure (TACIT), is proposed to support the IVIVS. Based on TACIT, toxicity that requires chronic administration and multiple secondary changes may be defined by the evaluation of changes in target cells that initiate the cascade of secondary events. A novel in vitro experimental system, the Integrated Discrete Multiple Organ Co-culture (IdMOC) system, which allows the evaluation of multiple organ toxicity under conditions allowing multiple organ interactions, is described as a promising technology.
Keywords: Species difference, Drug Toxicity, in vitro systems, cytotoxicity, Troglitazone, High content assays
Current Drug Safety
Title: Human-Based In Vitro Experimental Systems for the Evaluation of Human Drug Safety
Volume: 2 Issue: 3
Author(s): Albert P. Li
Affiliation:
Keywords: Species difference, Drug Toxicity, in vitro systems, cytotoxicity, Troglitazone, High content assays
Abstract: Accurate prediction of human drug safety remains a major challenge for drug development. Species-difference in drug toxicity represents a main reason for the difficulty in the prediction of human drug toxicity with nonhuman animal models. A combined in vitro-in vivo strategy (IVIVS), using human-based in vitro experimental systems to derive humanspecific information, and animal systems for in vivo variables, may lead to a more accurate prediction of human in vivo drug toxicity. The success of IVIVS requires in vitro models with human-specific drug metabolism, appropriate target cell populations, and relevant endpoints. A novel theory, the Target Cell Initiation Theory for drug-induced organ failure (TACIT), is proposed to support the IVIVS. Based on TACIT, toxicity that requires chronic administration and multiple secondary changes may be defined by the evaluation of changes in target cells that initiate the cascade of secondary events. A novel in vitro experimental system, the Integrated Discrete Multiple Organ Co-culture (IdMOC) system, which allows the evaluation of multiple organ toxicity under conditions allowing multiple organ interactions, is described as a promising technology.
Export Options
About this article
Cite this article as:
Li P. Albert, Human-Based In Vitro Experimental Systems for the Evaluation of Human Drug Safety, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668909
DOI https://dx.doi.org/10.2174/157488607781668909 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tetraspanins-Structural and Signalling Scaffolds that Regulate Platelet Function
Mini-Reviews in Medicinal Chemistry Cardiac Nuclear Imaging: Current Status and Future Directions
Current Medical Imaging Antiplatelet Treatment in Stroke: New Insights
Current Pharmaceutical Design Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Intracellular Protozoan Parasites of Humans: The Role of Molecular Chaperones in Development and Pathogenesis
Protein & Peptide Letters High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Current Pharmaceutical Analysis Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm
Current Drug Targets Quantification of Iron Deposition in the Brain of Hypertensive Patients using 3D-enhanced Susceptibility-weighted Angiography (ESWAN)
Current Medical Imaging The Antiplatelet and Antithrombotic Actions of Statins
Current Pharmaceutical Design Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry The Medical Complications of Anorexia Nervosa and Their Treatments
Current Women`s Health Reviews The Effect of Nicotine and Tobacco on Aortic Matrix Metalloproteinases in the Production of Aortic Aneurysm
Current Vascular Pharmacology Intravenous Glycoprotein IIb / IIIa Antagonists: Their Benefits, Problems and Future Developments
Current Pharmaceutical Design Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1), a Relevant Target for Diabetic Vasculopathy?
Cardiovascular & Hematological Disorders-Drug Targets Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders